Vasion Unveils Output Automation: Revolutionizing Output Management and Workflow Automation with a Cloud-Native Solution
4.11.2024 14:00:00 CET | Business Wire | Press release
Vasion®, a pioneer in serverless printing and orchestrated automation, announced the release of Vasion Output Automation™, the cloud-native SaaS solution that automates output management, enabling customers with opportunities to leverage cutting-edge AI.
Vasion Output Automation can eliminate reliance on outdated, on-premise infrastructure with a modern serverless approach, allowing leaders to apply AI, preparing even highly regulated, security-intensive organizations for the future. The solution centralizes administrative control for both business-critical print and end user print from a single console, seamlessly integrating back-end systems, automating output, enhancing data accuracy, digital document conversion, and routing.
“Vasion Output Automation is the next big step for our customers in their digital transformation journeys. With our orchestration automation platform, we bring together print, output, document, and process automation into one cloud-native solution that can help any business truly automate its end-to-end operations. I believe this will revolutionize the way businesses will operate today,” said Vasion Chief Product & Technology Officer Corey Ercanbrack.
Vasion Output Automation is the leading product of the Vasion 2024 Fall Product Launch. The core benefits include:
- Centralized Control and Reporting: The new Output Automation Console offers the flexibility to manage and troubleshoot document delivery directly from a centralized interface, streamlining operations and enhancing efficiency.
- Continuity and Reliability: Up-levelcapabilities with a drag-and-drop rules engine, on top of the powerful workflow engine, to streamline print and workflow processes, and automate document management through rule-based processes to enhance efficiency and accuracy.
- Cloud-Native Architecture:Eliminate costly on-premise print servers and centrally manage all critical document operations in the cloud, and enabling organizations to stay competitive by applying AI.
Additional Vasion Automate Product Innovations New this Fall:
Vasion Output Automation is part of the Vasion orchestrated automation platform, Vasion Automate. The Fall Launch also includes:
- Web Print: Guests can print directly from their web browser through a web portal link, without installing any additional servers, drivers, agents, or involvement from admins. IT leaders stay in complete control of their printing environment while keeping it simple for guests to print.
- Advanced Security: Enhancements include Off Network Cloud Print (ONCP) advancements, now fully supporting HP printers, mobile, and Chromebook devices.
- Mobile Scan: Digitize documents on the go from mobile devices, send to multiple destinations, like email, or cloud storage providers.
- AI-Enhanced Form Results: Simplify complex data analysis by using natural language to interface with form results, surfacing more insights, and delivering more impact from your data.
About Vasion:
Vasion revolutionized print automation with a cloud-native SaaS solution and is now a leader in intuitive orchestrated automation. Organizations can simplify their digital transformation using Vasion’s automation platform to integrate their print output with the digital work teams do today: capturing data, applying AI, OCR and ICR, building and automating workflows, digital signatures, universal content storage and search, built-in compliance controls, and cloud-based Output Automation™, combining end user print and output management. Vasion accelerates digital transformation by enabling leaders to leverage advanced integrations for AI, with robust security in a Zero Trust environment, and integrating, directing, and analyzing their automations through a single platform. PrinterLogic® and Vasion® are registered trademarks, and Vasion Automate™, Vasion Output Management™, and Vasion Print™ are trademarks of Vasion in the United States and/or other countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241104669739/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom